Abstract
The effects of maternal magnesium sulphate treatment on neonatal mineral status and parathyroid hormone secretory response were studied in 8 exposed and 27 control preterm infants during the first 2 wk of life. Antenatal magnesium sulphate resulted in hypermagnesaemia during the first 3-7 d of life without affecting other serum mineral concentrations.
Conclusion:
Early hypermagnesaemia was associated with hypercalciuria during the first 3 d and parathyroid hormone suppression up to the age of 2 wk in the exposed infants.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Calcium / blood
-
Calcium / urine
-
Female
-
Fetal Blood / chemistry
-
Humans
-
Infant, Newborn
-
Infant, Premature
-
Magnesium / blood
-
Magnesium / urine
-
Magnesium Sulfate / adverse effects*
-
Magnesium Sulfate / therapeutic use
-
Parathyroid Hormone / blood
-
Parathyroid Hormone / deficiency*
-
Phosphorus / blood
-
Phosphorus / urine
-
Pre-Eclampsia / drug therapy
-
Pregnancy
-
Tocolytic Agents / adverse effects*
-
Tocolytic Agents / therapeutic use
-
Trace Elements / blood*
-
Trace Elements / urine
Substances
-
Parathyroid Hormone
-
Tocolytic Agents
-
Trace Elements
-
Phosphorus
-
Magnesium Sulfate
-
Magnesium
-
Calcium